We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tobira Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
News

Tobira Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

Tobira Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
News

Tobira Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tobira Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Tobira Therapeutics Inc. has announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV.

These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing.

Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations.

"These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.

These data were presented at the 5th International Conference on HIV Pathogenesis, Treatment and Prevention, held July 19-23, 2009 in Cape Town, South Africa.
Advertisement